Status:
COMPLETED
An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Lead Sponsor:
Hanmi Pharmaceutical Company Limited
Conditions:
BPH
Benign Prostatic Hyperplasia
Eligibility:
MALE
19+ years
Brief Summary
In this study, BPH patients visited the institutions during the study period and the effectiveness and safety of the treatment of Tamsulosin(Hanmi Tams® Capsule) in real-practice. During the routine ...
Detailed Description
This study is a multicenter, prospective, non-interventional, observational study of men administering Tamsulosin(Hanmi Tams® Capsule) to treat BPH. Data will be collected from patients receiving rou...
Eligibility Criteria
Inclusion
- Male was diagnosed with Benign Prostatic Hyperplasia
- Those who first started taking Hanmi Tams®
- Those who voluntarily consented in writing to this study
Exclusion
- Patients for whom use of Hanmi Tams® is prohibited
Key Trial Info
Start Date :
July 15 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 24 2021
Estimated Enrollment :
4698 Patients enrolled
Trial Details
Trial ID
NCT05422677
Start Date
July 15 2019
End Date
August 24 2021
Last Update
June 22 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hanmi Pharmaceutical Company Limited
Seoul, South Korea, 05545